TG Therapeutics
TGTX
87 hedge funds and large institutions have $321M invested in TG Therapeutics in 2015 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 36 increasing their positions, 22 reducing their positions, and 11 closing their positions.
64% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 22
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
14% more capital invested
Capital invested by funds: $283M → $321M (+$38.2M)
5% more funds holding
Funds holding: 83 → 87 (+4)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
55% less call options, than puts
Call options by funds: $897K | Put options by funds: $1.98M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS AM
Chicago,
Illinois
|
+$17.7M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$3.78M |
| 3 |
EAM
Eventide Asset Management
Boston,
Massachusetts
|
+$2.04M |
| 4 |
Millennium Management
New York
|
+$2M |
| 5 |
SIP
Stoneridge Investment Partners
Radnor,
Pennsylvania
|
+$975K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$18.9M |
| 2 |
VAM
Visium Asset Management
New York
|
-$5.04M |
| 3 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
-$4.47M |
| 4 |
EDRS
Edmond de Rothschild (Suisse)
Geneva,
Switzerland
|
-$4.47M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$3.92M |
TGTX Hedge Fund Activity: Q4 2015 in Review
87 of the 3,824 institutional investors tracked by Wall St. Rank reported a position in TG Therapeutics (TGTX) for Q4 2015, worth a combined $321M — up 14% from $283M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new TGTX positions and 11 closed out — a net gain of 4 holders — while 36 added to existing stakes and 22 trimmed.
The largest buyer was UBS AM, adding an estimated $17.7M. The largest seller was State Street, cutting an estimated $18.9M.
- 87 institutional investors held TG Therapeutics (TGTX) as of Q4 2015, up from 83 in Q3 2015.
- Funds reported $321M of TG Therapeutics stock for Q4 2015, up 14% quarter-over-quarter.
- 15 funds opened new TG Therapeutics positions in Q4 2015 and 11 closed out, a net change of +4 holders.
- The largest TG Therapeutics buyer in Q4 2015 was UBS AM, an estimated $17.7M added.
- The largest TG Therapeutics seller in Q4 2015 was State Street, an estimated $18.9M sold.
Based on aggregated 13F filings for Q4 2015.